Boston Scientific Corporation $BSX Shares Sold by Calamos Advisors LLC

Calamos Advisors LLC decreased its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 2.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 871,657 shares of the medical equipment provider’s stock after selling 22,773 shares during the quarter. Calamos Advisors LLC owned about 0.06% of Boston Scientific worth $83,112,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in BSX. FWL Investment Management LLC acquired a new position in shares of Boston Scientific in the second quarter valued at about $26,000. Murphy & Mullick Capital Management Corp increased its holdings in shares of Boston Scientific by 200.0% in the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares during the period. Financial Consulate Inc. acquired a new position in shares of Boston Scientific in the third quarter valued at about $25,000. United Community Bank increased its holdings in shares of Boston Scientific by 115.7% in the third quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 147 shares during the period. Finally, Colonial Trust Co SC increased its holdings in shares of Boston Scientific by 502.2% in the third quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 231 shares during the period. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.34% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms recently commented on BSX. Stifel Nicolaus dropped their target price on Boston Scientific from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday. Jefferies Financial Group dropped their target price on Boston Scientific from $110.00 to $100.00 and set a “buy” rating on the stock in a report on Wednesday. Weiss Ratings lowered Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, February 4th. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Finally, Evercore dropped their target price on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $93.91.

Boston Scientific Stock Performance

NYSE BSX opened at $62.01 on Friday. The company has a market cap of $92.16 billion, a PE ratio of 25.95, a price-to-earnings-growth ratio of 1.08 and a beta of 0.78. The stock’s 50 day simple moving average is $68.45 and its 200-day simple moving average is $85.78. Boston Scientific Corporation has a 1-year low of $59.38 and a 1-year high of $109.50. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.68% and a net margin of 17.29%.The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter last year, the business posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, equities research analysts anticipate that Boston Scientific Corporation will post 3.37 EPS for the current fiscal year.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 results beat consensus — revenue grew ~11.6% and EPS topped estimates, showing underlying demand and execution that underpinned an initial share pop after the report. Boston Scientific Corporation (NYSE:BSX) Q1 2026 Earnings Call Transcript
• Positive Sentiment: Unusual call-option activity — heavy call buying was reported around the earnings period, indicating some traders are positioning for a rebound or event-driven upside. Traders Purchase High Volume of Boston Scientific Call Options (NYSE:BSX)
• Neutral Sentiment: Analyst views are mixed and the investment story is being reset — several coverage teams trimmed fair-value estimates and split between seeing a buy opportunity versus emphasizing execution risk. This creates divergence in short‑to‑medium term expectations. How The Investment Story Is Resetting For Boston Scientific (BSX) After Recent Analyst Shifts
• Negative Sentiment: Company trimmed 2026 profit and revenue outlook — management lowered full‑year guidance (Q2 trough flagged), which directly reduced near‑term earnings visibility and is the primary driver of the pullback. Boston Scientific cuts 2026 profit forecast, trims revenue growth view
• Negative Sentiment: Analysts slashed price targets after Q1/guidance — multiple firms trimmed targets (Truist, Baird, Needham, others), which amplifies selling pressure and reduces near‑term analyst support. Boston Scientific Analysts Slash Their Forecasts After Q1 Earnings
• Negative Sentiment: Multiple securities‑class action notices and law‑firm solicitations — several firms are soliciting lead‑plaintiff candidates tied to a July 2025–Feb 2026 class period, increasing legal risk and potential headline volatility. Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: Downgrades and new 52‑week low headlines — coverage noting downgrades and a 52‑week low contributes to technical selling and stops being hit. Boston Scientific (NYSE:BSX) Hits New 52-Week Low After Analyst Downgrade

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.